HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grégoire, V. Articles by Lonneux, M. Search for Related Content PubMed PubMed Citation Articles by Grégoire, V. Articles by Lonneux, M.

PET-Based Treatment Planning in Radiotherapy: A New Standard?

¹ Radiation Oncology Department, Université Catholique de Louvain, St. Luc University Hospital, Brussels, Belgium; ² Center for Molecular Imaging and Experimental Radiotherapy, Université Catholique de Louvain, St. Luc University Hospital, Brussels, Belgium; ³ Radiation Oncology Department, Katholiek Universiteit Leuven, Gasthuisberg University Hospital, Leuven, Belgium; and ⁴ Nuclear Medicine Department, Université Catholique de Louvain, St. Luc University Hospital, Brussels, Belgium

Correspondence: For correspondence or reprints contact: Vincent Grégoire, MD, PhD, Radiation Oncology Department, St. Luc University Hospital, 10 Avenue Hippocrate, 1200 Brussels, Belgium. E-mail: vincent.gregoire{at}imre.ucl.ac.be

Molecular imaging, in particular, PET, has brought an additional dimension to management for patients with cancer. ¹⁸F-FDG, which is the most widely available tracer, has been shown to be of value for the selection of target volumes in radiation oncology. Depending on its sensitivity and specificity, ¹⁸F-FDG has been shown to influence the selection of target volumes for non–small cell lung cancers (NSCLC) or for esophageal tumors. On the other hand, for tumors such as head and neck squamous cell carcinomas (HNSCC) and rectal carcinomas, convincing data on the value of ¹⁸F-FDG for target volume selection are still lacking. For target volume delineation, given that an adequate method is used for volume segmentation, the added value of ¹⁸F-FDG has been demonstrated for HNSCC and NSCLC. For both types of tumors, modifications in target volume delineation translated into differences in dose distribution compared with the results of CT scan–based plans. Studies are in progress for rectal tumors. Novel markers of tumor hypoxia or proliferation have the potential to modify the delineation of target volumes, allowing for "dose painting" in selected subvolumes. Finally, variations in tumor volume and viability during radiotherapy also are under intense investigation, potentially paving the way for so-called "theragnostic" or adaptive dose distribution during treatment. This review discusses how PET/CT might modify the current state of the art of radiotherapy planning.

Key Words: radiotherapy • PET • molecular imaging • treatment planning

COPYRIGHT © 2006 by the Society of Nuclear Medicine, Inc.

This article has been cited by other articles:

				E. P. Visser, M. E.P. Philippens, L. Kienhorst, J. H.A.M. Kaanders, F. H.M. Corstens, L.-F. de Geus-Oei, and W. J.G. Oyen Comparison of Tumor Volumes Derived from Glucose Metabolic Rate Maps and SUV Maps in Dynamic 18F-FDG PET J. Nucl. Med., June 1, 2008; 49(6): 892 - 898. [Abstract] [Full Text] [PDF]

				J. Czernin and H. R. Schelbert Introduction J. Nucl. Med., January 1, 2007; 48(1_suppl): 2S - 3S. [Full Text] [PDF]